Health
How Medicaid Cuts Trigger Drop in Weight-Loss Drug Prescriptions
Thousands of Americans may have lost access to popular weight loss medicines after four states stopped paying for them through Medicaid, a new study suggests. Researchers found that prescriptions fell sharply almost as soon as the coverage changes took effect.
Medicaid is a public health insurance program for people with limited incomes in the United States. It helps many families afford medical care and prescription drugs, but states can choose whether to cover medicines used specifically for weight loss.
On January 1, 2026, California, New Hampshire, Pennsylvania and South Carolina ended Medicaid coverage for certain weight loss drugs known as GLP-1 medicines. These treatments act like a natural hormone that helps control hunger and blood sugar.
Researchers from the University of Pittsburgh examined Medicaid prescription records from every state and Washington, D.C., covering January 2022 through March 2026. Their findings were published on November 16, 2026, in JAMA.
They compared the four states that stopped coverage with 10 states that continued paying for these medicines. In the states that ended coverage, quarterly prescriptions dropped from 2,914 to 421 for every 100,000 Medicaid members between late 2025 and early 2026.
That was an approximately 84% larger decline than the change seen in the comparison states. Pennsylvania experienced the steepest fall, with prescriptions down 95.5%.
The researchers estimated that between about 175,500 and 526,600 fewer Medicaid members may have filled prescriptions after the changes. This wide range reflects uncertainty because the records counted prescriptions, not individual patients.
The study also looked for signs that people had switched to similar drugs approved for diabetes. It found no clear increase in those prescriptions in the states that ended weight loss coverage.
This matters because stopping treatment can lead to weight regain for some patients, potentially affecting blood pressure, blood sugar and heart health. However, the study did not follow patients or measure whether their health actually worsened.
The findings show a close link between insurance decisions and access to treatment. They cannot prove that every missing prescription was caused by the policy change, since other insurance rules and private purchases were not fully captured.
Even with those limits, the sudden and unusually large drop offers strong evidence that coverage is a major barrier to continuing these medicines. The study highlights why changes in drug benefits deserve careful attention from doctors, patients and policymakers.
-
Lifestyle1 day agoNew Weight-Loss Injection Delivers 20% Weight Reduction
-
Lifestyle12 hours agoWeight-Loss Drug Access Drops as States End Medicaid Coverage
-
Health12 hours agoGreater Weight Loss on GLP-1 Drugs Linked to Better Health Outcomes
-
Health1 day agoNew Sleep Apnea Treatment Improves Breathing for Patients, See More
-
BREAKING NEWS2 months agoOgun Residents Raise Questions Over Yayi’s Campaign Spending
-
SPORTS1 month agoPremier League Referees Admit “Error of Judgement” Over Haaland Goal Against Man United
-
BREAKING NEWS4 months agoJUST-IN: 28-Year-Old Nigerian Man Deported From Ireland After Conviction for T£rror Offences and Mass M¥rder Threats in UK
-
BREAKING NEWS4 months agoOyo Police Bust Alleged Railway Vandalism Syndicate, Recover Stolen Rail Tracks Worth ₦200 Million
